Development and Validation of a Nomogram to Predict Ventricular Fibrillation During Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction

开发和验证用于预测急性心肌梗死患者经皮冠状动脉介入治疗期间室颤的列线图

阅读:1

Abstract

BACKGROUND: Ventricular fibrillation (VF) is a life-threatening complication of acute myocardial infarction (AMI), particularly in patients undergoing percutaneous coronary intervention (PCI). Early identification of high-risk patients is crucial for implementing preventive measures and improving outcomes. METHODS: This retrospective study analyzed clinical, laboratory, and angiographic data from 155 AMI patients to identify predictors of VF during PCI. Variable selection was performed using least absolute shrinkage and selection operator (LASSO) regression, elastic net regression, and random forest. Independent predictors were identified through multivariable logistic regression, and a nomogram was developed and validated to predict VF risk. Model performance was assessed using receiver operating characteristic (ROC) and calibration curves. RESULTS: Independent predictors of VF included diabetes (OR = 3.676 (1.365-10.668); p = 0.012), neutrophil-to-lymphocyte ratio (NLR) (odds ratio (OR) = 1.149 (1.053-1.265); p = 0.002), right coronary artery (RCA) intervention (OR = 3.185 (1.088-9.804); p = 0.037), Gensini score (OR = 1.020 (1.007-1.033); p = 0.003), and absence of beta blockers (OR = 0.168 (0.054-0.472); p = 0.001). The nomogram, incorporating these predictors, demonstrated a strong discriminative ability with an area under the ROC curve (AUC) of 0.882 (0.825-0.939) and good calibration (Hosmer-Lemeshow test, p = 0.769). The calibration curve showed a strong alignment between predicted probabilities and observed outcomes, with a mean absolute error of 0.033. CONCLUSIONS: This study identified diabetes, NLR, RCA intervention, Gensini score, and absence of beta-blocker use as key predictors of VF during PCI in AMI patients. A nomogram incorporating these factors showed strong predictive performance, aiding clinicians in identifying high-risk patients for targeted preventive strategies.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。